Document is current
Any future updates will be listed below
-
Authors
Soler, Zachary M.
Nash, Scott
Lane, Andrew P.
Patel, Zara M.
Lee, Stella E.
Fokkens, Wytske J.
Corbett, Mark
Jacob-Nara, Juby A.
Sacks, Harry
-
Funding
Funding for this research was provided by:
Sanofi
Regeneron Pharmaceuticals Inc.
Medical University of South Carolina
- License Information
-
More Information
Article History
Received: 6 June 2024
Accepted: 28 August 2024
First Online: 9 October 2024
Declarations
:
: Zachary M. Soler: Lyra, Novartis, Olympus, and Optinose – advisory board and/or consultant; GlaxoSmithKline, Regeneron Pharmaceuticals Inc., and Sanofi – speakers’ fees; Healthy Humming – Medical Director. Scott Nash, Harry Sacks: Regeneron Pharmaceuticals Inc. – employees, may hold stock and/or stock options in the company. Andrew P. Lane: Regeneron Pharmaceuticals Inc. and Sanofi – advisory board member. Zara M. Patel: Dianosic, InfiniteMD, Mediflix, Medtronic, and Optinose – advisory board and/or consultant; Olfera Therapeutics – Chief Medical Officer. Stella E. Lee: AstraZeneca, Genentech, GlaxoSmithKline, Lyra Therapeutics, Optinose, Regeneron Pharmaceuticals Inc. and Sanofi – clinical trial funding and advisory boards. Wytske J. Fokkens: BioInspire Technologies, GlaxoSmithKline, Meda Pharmaceuticals, and Sanofi – research grants. Mark Corbett, Juby A. Jacob-Nara: Sanofi − employees, may hold stock and/or stock options in the company.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
